secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001370053-25-000081
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma
--------------------------------------------------------------------------------

- CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.
- Jemperli royalties tiered: 8% up to $1B sales, 12% $1-1.5B, 20% $1.5-2.5B, 25% above $2.5B; GSK peak sales guide >£2B.
- Sagard monetization capped at $600M; expected paydown mid-2027 to Q2 2028.
- Biopharma Co pipeline: rosnilimab (Phase 2b RA, Phase 2 UC top-line Nov/Dec 2025), ANB033 (celiac Ph1b), ANB101 (Ph1a).
- Separation targeted by year-end 2026; taxable but minimizing taxes; subject to board and SEC approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000081/0001370053-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000081/anab-20250929.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer